Arthritis

Ex vivo study
#Arthritis #Interferonopathies #Lupus #Protein inhibitor

UK company identifies potential new treatment for lupus

Domainex has revealed human ex vivo data indicating that DMXD-011 could be effective in treating interferonopathies such as lupus, Sjögren’s syndrome, and scleroderma. The drug candidate is an inhibitor of protein kinases TBK1 and IKK-epsilon, which previous studies suggest should be highly-effective in the treatment of inflammatory diseases. The efficacy of DMXD-011… Read More

#News

#Arthritis #Clinical trials #Covid-19 #Drug therapy

Covid-19 study boosts Swedish rheumatoid arthritis programme 

Cyxone, a Swedish clinical stage biotech company developing disease modifying therapies for diseases such as rheumatoid arthritis (RA), confirms the previously demonstrated favourable safety and tolerability profile for its drug candidate Rabeximod, in the Clinical Study Report from its exploratory Phase II study in Covid-19 patients.   Other… Read More

#News

Knee pain
#Arthritis #Chronic pain #Pharmacology

Altasciences and Virpax conduct first-in-human study of chronic pain

Virpax Pharmaceuticals has chosen Altasciences to conduct a first-in-human study of Epoladerm (diclofenac epolamine) for chronic pain associated with osteoarthritis of the knee. This treatment is supplied in a pre-filled device for administration as a topical spray film.  The study  The study will be conducted in the second quarter of 2022… Read More

#News